{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:54:02Z","timestamp":1788285242568,"version":"build-2803163510"},"reference-count":53,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T00:00:00Z","timestamp":1437004800000},"content-version":"unspecified","delay-in-days":196,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold>The aim of this study was to conduct a review of health technology assessments (HTAs) in cervical cancer screening to highlight the most common metrics HTA agencies use to evaluate and recommend cervical cancer screening technologies.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>The Center for Reviews and Dissemination (CRD), MedLine, and national HTA agency databases were searched using keywords (\u201ccervical cancer screening\u201d OR \u201ccervical cancer\u201d OR \u201ccervical screening\u201d) and \u201cHTA\u201d from January 2000 to October 2014. Non-English language reports without English summaries, non-HTA reports, HTAs unrelated to a screening intervention and HTAs without sufficient summaries available online were excluded. We used various National Institute for Health and Care Excellence (NICE) methods to extract key assessment criteria and to determine whether a change in screening practice was recommended.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>One hundred and ten unique HTA reports were identified; forty-four HTAs from seventeen countries met inclusion criteria. All reports evaluated technologies for use among women. Ten cervical screening technologies were identified either as an intervention or a comparator. The most common outcome metric evaluated was diagnostic accuracy, followed by economic effectiveness. Additional outcome metrics such as the use of adjunct testing, screening intervals, and age-specific testing were commonly evaluated. Nearly one-third (fifteen of forty-four) of HTAs recommended a change in practice.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold>This review highlights popular metrics used in HTAs for cervical cancer screening. Clinical and economic effectiveness metrics have been consistently assessed in HTAs, while the use of adjunct testing, screening intervals, and age-specific screening became increasingly prevalent from after 2007. Moreover, we observed an increase in optimized recommendations after 2007.<\/jats:p>","DOI":"10.1017\/s0266462315000197","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T12:28:39Z","timestamp":1437049719000},"page":"171-180","source":"Crossref","is-referenced-by-count":20,"title":["HEALTH TECHNOLOGY ASSESSMENT ON CERVICAL CANCER SCREENING, 2000\u20132014"],"prefix":"10.1017","volume":"31","author":[{"given":"Betsy J.","family":"Lahue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Baginska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"key":"S0266462315000197_ref050","volume-title":"Assessment of human papilloma virus (HPV) testing in primary screening for cervical cancer in France","author":"Latapy","year":"2004"},{"key":"S0266462315000197_ref030","volume-title":"Screening for cervical cancer: A systematic evidence review for the U.S. Preventive Services Task Force","author":"Vesco","year":"2011"},{"key":"S0266462315000197_ref052","unstructured":"Health Technology Assessment International (HTAi). About HTAi: Mission. HTAi Website. http:\/\/www.htai.org\/about-htai\/mission.html (accessed November 2013)."},{"key":"S0266462315000197_ref008","doi-asserted-by":"crossref","DOI":"10.57598\/R38C","volume-title":"Cervical cancer screening and human papillomavirus (HPV) testing","author":"Hulstaert","year":"2006"},{"key":"S0266462315000197_ref046","volume-title":"Adoption of liquid-based cytology: Technological evaluation","author":"Lapointe","year":"2008"},{"key":"S0266462315000197_ref045","volume-title":"The use of liquid based cytology (LBC) and conventional pap smear (CPS) for cervical screening in Denmark: A health technology assessment","year":"2005"},{"key":"S0266462315000197_ref024","doi-asserted-by":"publisher","DOI":"10.3310\/hta13510"},{"key":"S0266462315000197_ref036","volume-title":"Avalia-t 2013\/01","author":"Queiro Verdes","year":"2013"},{"key":"S0266462315000197_ref033","article-title":"Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors","volume":"36","author":"Ronco","year":"2012","journal-title":"Epidemiol Prev"},{"key":"S0266462315000197_ref010","volume-title":"Review on the medical and health economic evidence for an inclusion of colposcopy in primary screening programs for cervical cancer","author":"Nocon","year":"2007"},{"key":"S0266462315000197_ref001","volume-title":"Comprehensive cervical cancer prevention and control:a healthier future for girls and women","year":"2013"},{"key":"S0266462315000197_ref007","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"S0266462315000197_ref018","volume-title":"Human papillomavirus testing for cervical screening","year":"2003"},{"key":"S0266462315000197_ref044","volume-title":"Health technology assessment","author":"Muth","year":"2003"},{"key":"S0266462315000197_ref009","author":"Varela Lema","year":"2010"},{"key":"S0266462315000197_ref032","first-page":"e1","article-title":"Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening","volume":"36","author":"Ronco","year":"2012","journal-title":"Epidemiol Prev"},{"key":"S0266462315000197_ref014","volume-title":"Research for development of an optimal policy strategy for prevention and control of cervical cancer in Thailand","year":"2008"},{"key":"S0266462315000197_ref017","volume-title":"Computer-assisted image analysis for cervical screening","year":"2003"},{"key":"S0266462315000197_ref037","volume-title":"Benefit assessment of HPV testing in primary screening for cervical cancer","year":"2011"},{"key":"S0266462315000197_ref031","volume-title":"Population screening for cervical cancer","year":"2011"},{"key":"S0266462315000197_ref043","volume-title":"Screening for cervical cancer: Recent advances","year":"2002"},{"key":"S0266462315000197_ref053","unstructured":"European Network for Health Technology Assessment (EUnetHTA). Collaborations. EUnetHTA Website. http:\/\/www.eunethta.eu\/collaborations (accessed November 2013)."},{"key":"S0266462315000197_ref027","volume-title":"Cervista\u2122 HPV 16\/18 for the identification of strains of the human papillomavirus associated with cervical cancer","year":"2009"},{"key":"S0266462315000197_ref011","first-page":"1","article-title":"Adjunctive colposcopy technologies for examination of the uterine cervix\u2013DySIS, LuViva Advanced Cervical Scan and Niris Imaging System: A systematic review and economic evaluation","volume":"17","author":"Wade","year":"2013","journal-title":"NIHR Health Technol Assess"},{"key":"S0266462315000197_ref026","volume-title":"Human papillomavirus triage test for women with possible or definite low-grade squamous intraepithelial lesions","year":"2009"},{"key":"S0266462315000197_ref023","volume-title":"Liquid-based cytology for screening of precursors of cervical cancer","year":"2008"},{"key":"S0266462315000197_ref040","article-title":"Liquid-based cytology and human papillomavirus testing in cervical cancer screening","volume":"85","author":"Noorani","year":"2003","journal-title":"Canada Coordinating Office for Health Technology Assessment (CCOHTA)"},{"key":"S0266462315000197_ref005","unstructured":"National Institute of Health (NIH). Fact sheet cervical cancer. http:\/\/report.nih.gov\/nihfactsheets\/Pdfs\/CervicalCancer(NCI).pdf. 2010 (accessed December 2014)."},{"key":"S0266462315000197_ref020","doi-asserted-by":"publisher","DOI":"10.3310\/hta8200"},{"key":"S0266462315000197_ref028","volume-title":"Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV DNA testing in primary cervical cancer screening in Germany","author":"Sroczynski","year":"2010"},{"key":"S0266462315000197_ref021","volume-title":"Performance of commercially available HPV tests. NZHTA technical brief","author":"Stephenson","year":"2007"},{"key":"S0266462315000197_ref012","volume-title":"P16\/Ki-67 dual stain in the triage of PAPIII\/IIID cytology in cervical cancer screening","author":"Kisser","year":"2013"},{"key":"S0266462315000197_ref051","volume-title":"Assessment of effectiveness and costeffectiveness of HPV testing in primary screening for cervical cancer","author":"Mittendorf","year":"2007"},{"key":"S0266462315000197_ref006","volume-title":"Screening for cervical cancer: A decision analysis for the U.S. preventive services task force","author":"Kulasingam","year":"2011"},{"key":"S0266462315000197_ref003","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.06.025"},{"key":"S0266462315000197_ref022","volume-title":"Liquid-based techniques for cervical cancer screening: Systematicreview and cost-effectiveness analysis","author":"Krahn","year":"2008"},{"key":"S0266462315000197_ref035","doi-asserted-by":"publisher","DOI":"10.3310\/hta18230"},{"key":"S0266462315000197_ref029","doi-asserted-by":"publisher","DOI":"10.3310\/hta15030"},{"key":"S0266462315000197_ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4180","article-title":"Liquid-based cytology in cervical screening:a rapid and systematic review","volume":"4","author":"Payne","year":"2000","journal-title":"Health Technol Assess"},{"key":"S0266462315000197_ref013","volume-title":"Zilico hand-held device for rapid cervical cancer detection","year":"2010"},{"key":"S0266462315000197_ref038","first-page":"311","article-title":"Effectiveness and cost effectiveness of automated and semi-automated cervical screening devices: A systematic review of the literature","volume":"13","author":"Broadstock","year":"2001","journal-title":"N Z Med J"},{"key":"S0266462315000197_ref016","volume-title":"Human papillomavirus testing in women with cytological prediction of low-grade abnormality","year":"2002"},{"key":"S0266462315000197_ref019","volume-title":"Guidance on the use of liquid-based cytology for cervical screening. NICE Technology Appraisal","year":"2003"},{"key":"S0266462315000197_ref048","doi-asserted-by":"publisher","DOI":"10.3310\/hta9130"},{"key":"S0266462315000197_ref039","volume-title":"Liquid based cytology for cervical screening MSAC","year":"2002"},{"key":"S0266462315000197_ref025","first-page":"1122","volume-title":"Automation assisted and liquid based cytology for cervical cancer screening","year":"2009"},{"key":"S0266462315000197_ref015","article-title":"Health technology assessment report: Computer-assisted Pap test for cervical cancer screening","volume":"36","author":"Della Palma","year":"2012","journal-title":"Epidemiol Prev"},{"key":"S0266462315000197_ref041","volume-title":"Human papillomavirus testing in primary care cervical cancer screening","year":"2000"},{"key":"S0266462315000197_ref004","doi-asserted-by":"publisher","DOI":"10.1016\/j.whi.2010.07.002"},{"key":"S0266462315000197_ref034","volume-title":"What is the clinical and cost effectiveness of human papillomavirus (HPV) testing, followed by liquid-based cytology triage of positive results, in primary screening for cervical cancer?","year":"2012"},{"key":"S0266462315000197_ref047","volume-title":"Efficacy, effectivity and efficiency of liquid cytology for cervical cancer screening and HPV infection diagnosis","author":"Ruiz-Arag\u00f3n","year":"2013"},{"key":"S0266462315000197_ref002","doi-asserted-by":"publisher","DOI":"10.1363\/3601104"},{"key":"S0266462315000197_ref049","volume-title":"Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in South Korea","author":"Ko","year":"2014"}],"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0266462315000197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T08:34:34Z","timestamp":1748507674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0266462315000197\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"alternative-id":["S0266462315000197"],"URL":"https:\/\/doi.org\/10.1017\/s0266462315000197","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"value":"0266-4623","type":"print"},{"value":"1471-6348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}